Portfolio company
Eloxx Pharmaceuticals
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops ribonucleic acid modulating medicines to treat patients with rare kidney and skin diseases caused by nonsense mutations.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Chinook Therapeutics
This biopharmaceutical company develops precision medicines for patients with rare and severe chronic kidney diseases.
Phlox Therapeutics
This company develops RNA-based gene therapies to treat patients with rare genetic heart diseases, including cardiomyopathies and laminopathies.
ARTHEx Biotech
This clinical-stage biotechnology company develops RNA-based treatments for patients with rare neuromuscular genetic diseases, including myotonic dystrophy type 1.
Nionyx Bio
The company develops adeno-associated virus gene therapies for patients with genetic kidney diseases.
Typewriter Therapeutics
The company develops RNA-based genetic medicines for patients with cancer, autoimmune conditions and rare genetic diseases.
Estuary Biotherapeutics
This biotechnology company develops targeted genetic medicines for patients with serious kidney conditions, specifically autosomal dominant polycystic kidney disease.
EveryONE Medicines
The company develops individualized antisense oligonucleotide therapies for children with rare life-threatening neurodegenerative diseases caused by unique genetic mutations.
OxThera AB
This biopharmaceutical company develops bacteria-based therapies to treat patients with primary hyperoxaluria and other rare kidney diseases.